Targeting p53 by PTD-mediated transduction

Area of Science:

• Oncology
• Molecular Biology
• Biotechnology

Background:

• The p53 tumor suppressor is a critical target for cancer treatment strategies.
• Current approaches include p53 gene overexpression and small molecule-based rescue of mutant p53.
• p53 peptides show promise in activating p53 responses in various cancer cell types.

Purpose of the Study:

• To investigate the potential of protein transduction domain (PTD)-mediated delivery for p53 peptides.
• To enhance the cellular uptake and functional impact of p53-based therapeutic cargos.
• To explore the role of influenza hemagglutinin protein (HA2) in improving PTD delivery.

Main Methods:

• Utilized PTD-conjugated peptides targeting the p53 carboxyl terminus for cell entry.
• Investigated PTD-mediated cellular uptake via macropinocytosis.
• Employed the influenza virus hemagglutinin protein (HA2) to disrupt macropinocytosomes and facilitate cargo escape.

Main Results:

• PTD-mediated delivery successfully introduced p53 peptides into cells.
• PTD-mediated transfer occurred through macropinocytosis.
• Co-delivery with HA2 significantly enhanced the escape of PTD-cargos from macropinocytosomes, boosting functional outcomes.

Conclusions:

• PTD technology offers a viable strategy for delivering p53 peptides and other large molecular cargos into cells.
• The destabilization of macropinocytosomes by HA2 is crucial for efficient intracellular cargo delivery.
• This combined approach holds significant potential for advancing p53-based tumor therapies.